logo

LYKALABS vs MANGALAM: Stock Comparison

LYKALABS vs MANGALAM DRUG & CHEMUpdated 1 Jul 26, 4:08 PM ISTNSE & company filings

LYKALABS is the larger company by market capitalisation. LYKALABS shows a higher ROE, faster revenue growth and lower leverage, while MANGALAM DRUG & CHEM shows a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

LYKALABS leads 5; MANGALAM leads 2 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

LYKALABSMANGALAM

Valuation lens

What price are you paying?

Market CapContext only
₹308 Cr
₹47 Cr
P/E RatioSame reading
0x
—
P/B RatioSame reading
2.67x
—
EPSLYKALABS has the higher reading
₹0.57 ✓
₹-4.83
Book ValueContext only
₹25.12
₹65.11
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
LYKALABS is the larger company
₹308 Cr vs ₹47 Cr
EPS
LYKALABS has higher earnings per share
₹0.57 vs ₹-4.83
Revenue Growth (TTM YoY)
LYKALABS has faster revenue growth
0% vs -7.5%
ROE
LYKALABS has a higher ROE
-37.11% vs -42.41%
ROCE
MANGALAM has a higher ROCE
-15.52% vs -22.29%
Net Margin
LYKALABS has a higher net margin
-7.81% vs -19.13%
Operating Margin
MANGALAM has a higher operating margin
-13.69% vs -24.74%
Debt to Equity
LYKALABS has lower leverage
0.56x vs 0.99x

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLYKALABSMANGALAM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLYKALABSMANGALAM
Live Price₹74.83₹29.57
Day Change1.19%-2.79%
Volume88,55611,157
52-Week High₹98.9₹71.99
52-Week Low₹44.1₹22.8
Distance from 52W High-24.34%-58.92%

Valuation

MetricLYKALABSMANGALAM
Market Cap₹308 Cr₹47 Cr
P/E Ratio0x—
P/B Ratio2.67x—
EPS₹0.57₹-4.83
Book Value₹25.12₹65.11
Dividend Yield0%0%

Growth

MetricLYKALABSMANGALAM
Revenue Growth (TTM YoY)0%-7.5%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricLYKALABSMANGALAM
ROE-37.11%-42.41%
ROCE-22.29%-15.52%
Net Margin-7.81%-19.13%
Operating Margin-24.74%-13.69%
Debt to Equity0.56x0.99x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricLYKALABSMANGALAM
Promoter Holding58.45%35.65%
FII Holding0.15%▼ 0.02 pp0.11%
DII Holding0.66%0%
Public Holding40.73%▲ 0.01 pp64.24%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and MANGALAM DRUG & CHEM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.